8.30AM - 6.30PM EST | 5.30AM - 3.30PM PST

8:30 am Online Registration & Coffee Networking Session

8:50 am Chair’s Opening Remarks

Spotlight on Clinical Progress for Inflammasome Targeted Therapies

9:00 am Exploring Small Molecule Inflammasome Inhibitors in Retinal Disease

  • Paul Ashton Chief Executive Officer, Inflammasome Therapeutics

9:30 am Inhibiting the NLRP3 Inflammasome Activation Signal in Chronic Disease Through Connexin Hemichannel Modulation

  • Colin Green Co-founder & Chief Scientific Officer, OcuNexus Therapeutics

10:00 am Live Q&A

  • Paul Ashton Chief Executive Officer, Inflammasome Therapeutics
  • Colin Green Co-founder & Chief Scientific Officer, OcuNexus Therapeutics
  • Hal Hoffman Professor of Pediatrics & Medicine, University of California at San Diego & Rady Children's Hospital of San Diego

Synopsis

Have the speakers answer your questions

10:20 am Morning Refreshments & Virtual Speed Networking

DISCOVERY STREAM

TRANSLATIONAL STREAM

Understanding the Molecular Mechanisms of the Inflammasome

Advances in Developing More Translatable Pre-Clinical Models

11.00 Inflammasome Activation in Age Related Diseases: Lessons from Longevity Outliers

Johannes Grosse, Senior Director, Vir Biotechnology

11.30 The Promise & Reality of Inflammasome in Inflammatory Bowel Disease: Lessons from Experimental Models

Vishal Singh, Assistant Professor, Nutritional Sciences & Microbiome, Penn State University

12.00 Panel Discussion: Challenges & Opportunities of Inflammasome Targeted Drug Discovery

Mike Crackower, Head, Research & Development, Ventus Therapeutics

1.00 Live Q&A Session

11.00 Activation & Mitigation of Different Inflammasomes in Disease Models

Jenny Ting, Distinguished Professor, Genetics, UNC School of Medicine

11.30 Navigating Intradermal LPS Challenge as Human Inflammasome Model

Manon Jansen, Senior Clinical Scientist, Centre for Human Drug Research

12.00 Targeting Inflammasome as Potential Treatment for Skin & Neurodegenerative Diseases

Yiumo Chan, Chief Scientific Officer, Twi Biotechnology

1.00 Live Q&A Session

1:20 pm Lunch & Networking

DISCOVERY STREAM

TRANSLATIONAL STREAM

Improve Understanding of what is Happening Upstream & Downstream of the Inflammasome

Advancing in Biomarkers for Assessing Target Engagement

2.20 Exploring the Next Frontier in Therapeutic Targeting of Inflammatory Cell Death: Gasdermin D

Iain Kilty, Chief Scientific Officer, Quench Bio

2.50 Targeting of Gasdermin D to Limit Inflammasome Mediated Responses

Kate FitzGerald, Professor, University of Massachusetts Medical School

3.20 Live Q&A Session

 

2.20 Biomarkers, Alzheimer’s Disease & the Inflammasome

Juan Pablo de Rivero Vaccari, Research Assistant Professor, University of Miami

2.50 Panel Discussion: Pharmacokinetics & Biomarkers for First in Human Studies

Panellist to be confirmed

3.20 Live Q&A Session

3:20 pm Speed Networking & Afternoon Break

Developments in Novel Therapeutic Modalities Effectively Targeting the Inflammasome

4:10 pm Inhibition of NLRP3 Expression by Exosome Delivery of Antisense Oligonucleotide (ASO)

  • Joanne Lim Senior Scientist, Cellular Immunology, Codiak Biosciences

Exploring Novel Therapeutic Targets

4:40 pm Inflammasomes: Gatekeepers at the front line of skin health

  • Vincent Gruber Director of New Technology, JEEN International Corporation

5:10 pm Novel Approach to Identify & Validate Uric Acid-Driven Mediators of Inflammation

  • Scott Bowers Associate Director, Preclinical Pharmacology, Horizon Therapeutics

5:40 pm Live Q&A

  • Joanne Lim Senior Scientist, Cellular Immunology, Codiak Biosciences
  • Vincent Gruber Director of New Technology, JEEN International Corporation
  • Scott Bowers Associate Director, Preclinical Pharmacology, Horizon Therapeutics

Synopsis

Have the speaker answer your questions

COVID Induced Inflammation – The Role of the Inflammasome

6:00 pm Panel Discussion: A Three-Tiered Approach to Better Understand the Role of the Inflammasome in COVID-19 Induced Inflammation

6:30 pm Chair’s Closing Remarks